Equity Gap congrates portfolio company EnteroBiotix, which has successfully completed a £27m financing round with the support of new and existing investors, including Equity Gap members. The clinical-stage biotechnology company will use the funding to advance its clinical trials.
This follows EnteroBiotix’s earlier news announcing that its first patient has been dosed in a Phase 2 Study of EBX-102-02 in Irritable Bowel Syndrome. Having invested in the business since its first funding round, these are exciting announcements as EnteroBiotix continues to grow and transform the standard of care for gut microbiome-related health conditions.
Enterobiotix complete £27m round to advance clinical trials
